TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05141240

Intervention type: DRUG
Intervention: Ribiciclib
Description: Participants who initiated CDK4/6i therapy

Intervention type: DRUG
Intervention: Palbociclib
Description: Participants who initiated CDK4/6i therapy

Intervention type: DRUG
Intervention: Abemaciclib
Description: Participants who initiated CDK4/6i therapy
Study: NCT02940587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study: NCT02580305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVN-502
Description: Once-daily, tablets, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVN-502
Description: Once-daily, tablets, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, tablets, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil HCl (10 mg, once a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil HCl (10 mg, once a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: Donepezil HCl (10 mg, once a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Study: NCT02370927

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Starch
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein + pea starch
Description: Pulse extruded cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea starch + pea protein
Description: Pulse extruded cereal
Study: NCT01955967

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Study: NCT03167242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
Study: NCT02507453

Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: mass/weight perception estimation
Description: estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)

Intervention type: DEVICE
Group type: OTHER
Intervention: ESA short-arm human centrifuge (SAHC)
Study: NCT03818724

Intervention type: DEVICE
Intervention: CoolLoop® cryoablation system
Description: Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
Study: NCT04343287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421
Description: The active control with BRM421 solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle solution
Study: NCT01800734

Intervention type: OTHER
Group type: OTHER
Intervention: Clamp-Mixed Meal Arm
Description: Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
Study: NCT00833768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: 800mg tablets to be taken orally with meals three times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for sevelamer carbonate
Description: Placebo tablets to be taken orally with meals three times per day
Study: NCT04183036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoclip papillaplasty
Description: Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
Study: NCT02842762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right ventricular epicardial pacing
Description: The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cardiac surgery
Description: Elective cardiac surgery, with use of cardiopulmonary bypass.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: Elective cardiac surgery, with use of cardiopulmonary bypass.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 3D TEE
Description: Intraoperatively, all patients will be monitored by means of TEE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D TEE
Description: Intraoperatively, all patients will be monitored by means of TEE

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pacemaker lead
Description: All patients will have a epicardial pacemaker lead in situ.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker lead
Description: All patients will have a epicardial pacemaker lead in situ.
Study: NCT02030002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APC Flash-Free Adhesive Coated Appliance System
Description: APC Flash-Free Adhesive Coated Appliance System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APC II Adhesive Coated Appliance System
Description: APC II Adhesive Coated Appliance System
Study: NCT00774930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: deep s.c. injection, 120 mg, every 4 weeks (±3 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
Study: NCT03385343

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VLE imaging for staging EAC
Description: Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
Study: NCT01097707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307
Description: Administered orally, daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307
Description: Administered orally, daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307
Description: Administered orally, daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307
Description: Administered orally, daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, daily for 24 weeks
Study: NCT01652495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
Study: NCT00480935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (Sutent)
Description: Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
Study: NCT04948281

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03093103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
Study: NCT01843153

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Study: NCT04367259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis
Description: Temporomandibular joint arthrocentesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis
Description: Temporomandibular joint arthrocentesis
Study: NCT01986270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: 40mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: 80mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Description: 25mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Description: 50mg oral
Study: NCT00870077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProWHEY 94 CFM, SponserR
Description: 3 times 20g per day
Study: NCT03884946

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Getting Off App
Description: A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Getting Off App
Description: A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included.
Study: NCT00939822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg Simvastatin/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01072630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
Study: NCT03167242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
Study: NCT01072630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Study: NCT01846377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G4H-Diab-Nano
Description: The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
Study: NCT00810433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GO-LIF - Guided Oblique Lumbar Interbody Fusion
Description: All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused.
Study: NCT02005770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT04138108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
Study: NCT00089921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 60 mg capsule three times daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 30 mg capsule three times daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules three times daily and one tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 100 mg tablet once daily for 12 weeks
Study: NCT04694261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SM-ART
Description: Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
Study: NCT03943472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune inhibitors
Description: Immune inhibitors
Study: NCT00020735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT00920075

Intervention type: DRUG
Intervention: Alendronate (Fosamax)
Description: Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
Study: NCT04329468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS-MCE
Description: The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel.
Study: NCT01129700

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: short-course preoperative chemoradiotherapy
Description: Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day).
Study: NCT03167242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.